Sam Renwick is founding principal at RNA Advisors and leads the firm’s life sciences and healthcare initiatives. He has 25 years of experience building and running the life science valuation and consulting groups at firms like Huron, SVB, Salter Group (now FTI) and BPM.
Mr. Renwick specializes in providing valuation, forecasting and advisory services to technology, biopharmaceutical, medical device and equipment, diagnostic companies, and clinical research and manufacturing organizations, as well as other IP-centric technology companies.
His experience includes buy-side and sell-side advisory engagements for licensing, financing and mergers and acquisitions, as well as for tax and financial reporting matters for large public companies to small venture-backed enterprises.
Whether developing dynamic, patient flow models for late-clinical therapeutic assets, developing financial models to assist in decision analysis for a technology company or developing an opinion of value for a security for compliance purposes, he combines his breadth of industry knowledge with deep expertise in finance and financial models to create compelling communications regarding the value proposition of an asset, portfolio of assets or a company. Sam has worked with more than 500 life sciences and technology companies in his career.
Sam holds an MBA from the UCLA Anderson School of Business where he earned the J. Fred Weston award for finishing at the top of his class in finance following a B.A. in Economics and Business from Westmont College.